

April 27, 2025

The Executive Director  
 Bangladesh Securities and Exchange Commission  
 Commission Bhaban  
 E-6/C, Agargaon  
 Sher-e-Bangla Nagar Administrative  
 Dhaka-1207

Subject: Disclosure of Price Sensitive Information (PSI) regarding the Un-audited 3<sup>rd</sup> Quarter Financial Statements of Ambee Pharmaceuticals PLC for the period ended 31<sup>st</sup> March 2025.

Dear Sir,

In compliance with Regulation 16 (2) of the Dhaka Stock Exchange (Listing) Regulations, 2015, we are pleased to submit the Price Sensitive Information (PSI) of Ambee Pharmaceuticals PLC regarding the Un-audited Financial Statements for the 3<sup>rd</sup> Quarter ended 31<sup>st</sup> March 2025, which were duly approved by the Board of Directors at their meeting held on 27<sup>th</sup> April 2025 at 3:00 P.M., as detailed below:


Sl. No.	Particulars	Jan'25 to Mar'25	Jan'24 to Mar'24	Jul'24 to Mar'25	Jul'23 to Mar'24
01.	Earnings Per Share (EPS)	0.85	0.80	2.17	2.00
02.	Net Operating Cash Flow Per Share (NOCFPS)	-	-	(5.69)	(12.21)

		As on 31.03.2025	As on 30.06.2024		
03.	Net Asset Value (NAV)	13.43	12.26	-	-

This is for your kind information please.

Thanking you

For Ambee Pharmaceuticals PLC

  
 Mohammad Amir Hossain  
 Company Secretary

Cc: The Dhaka Stock Exchange PLC  
 The Chittagong Stock Exchange PLC